You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

  • Technology appraisal guidance
  • Reference number: TA171
  • Published:  18 June 2009
  • Last updated:  26 June 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Consultee and commentator comments on the ACD

  • Celgene

  • Department of Health

  • Janssen-Cilag

  • Macmillan Cancer Relief

  • Myeloma UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO

  • Sandwell PCT

  • UK Myeloma Forum and British Society for Haematology


This page was last updated: 30 March 2010

Back to top